Semaglutide
FDA ApprovedAlso known as: Ozempic, Wegovy, Rybelsus
GLP-1 AgonistLast reviewed: April 28, 2026
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
Mechanism of Action
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
Common Uses
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
Known Risks
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
Regulatory Status
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection (Ozempic/Wegovy)
Typical Dose
0.25 mg → 2.4 mg (titrated over 16–20 weeks)
Frequency
Once weekly
Cycle Length
Ongoing — not typically cycled
Always start at 0.25 mg/week and titrate slowly to minimize GI side effects. Inject in abdomen, thigh, or upper arm. Rotate sites.
Oral tablet (Rybelsus)
Typical Dose
3 mg → 14 mg (titrated)
Frequency
Once daily
Cycle Length
Ongoing
Take on empty stomach with no more than 4 oz of water. Wait 30 minutes before eating or taking other medications.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.